ThromboGenics announced that it has resubmitted a Biologics License Application (BLA) with the FDA for ocriplasmin intravitreal injection 2.5mg/mL for the treatment of symptomatic vitreomacular adhesion (VMA) including macular hole.
SIGN IN WITH ONE OF YOUR SOCIAL ACCOUNTS
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH ONE OF YOUR SOCIAL ACCOUNTS
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a password reset link.
ENTER NEW PASSWORD